Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.

@article{Ratain1991PharmacologicallyBD,
  title={Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.},
  author={Mark J. Ratain and Rosemarie Mick and Richard L. Schilsky and Nicholas John Vogelzang and Frances Berezin},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1991},
  volume={9 8},
  pages={1480-6}
}
We have previously demonstrated that individualized dosing of etoposide (VP16) by 72-hour infusion is feasible and that the extent of leukopenia is a function of plasma concentration, pretreatment WBC (WBCp), albumin (ALB), performance status (PS), and bone marrow function (based on transfusion requirements). In the current study, 45 patients were randomized between a fixed dose of VP16 (125 mg/m2/d) versus individualized dosing to a target WBC nadir (WBCN) of 1,700/microL. The total dose was… CONTINUE READING

From This Paper

Topics from this paper.
39 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

Similar Papers

Loading similar papers…